Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis
Date Time Share Case Western Reserve and Atelerix Life Sciences Inc. sign option license to develop new therapeutic approach to opioid crisis Novel small molecule technology reverses life-threatening opioid-induced respiratory depression without diminishing pain relief Case Western Reserve University and Atelerix Life Sciences Inc., a Charlottesville, Virginia-based biotechnology company, have signed a two-year option to license a novel family of small molecules called Active Thiol-Based Compounds (ATBC’s) to prevent or reverse life-threatening opioid-related side effects. The lead compoun...